Hyderabad, March 21 -- Zydus Lifesciences on Saturday announced the launch of Semaglutide Injection in India under the brand names SEMAGLYN (TM) , MASHEMA (TM) and ALTERME (TM) , following patent expiry.
The drug has been approved by the Drugs Controller General of India (DCGI) for the treatment of Type 2 Diabetes Mellitus and obesity.
In a release, the company said the product will be offered through an innovative reusable multi-dose pen device, a departure from conventional single-dose pens.
The prefilled cartridge is designed for use with a patient-friendly reusable pen, for which Zydus holds exclusive rights.
The device enables patients and clinicians to select and administer different dose strengths from a single pen, improving con...